Advanced search
Publication Cover
Journal of Medical Economics Volume 5, 2002 - Issue 1-4
Submit an article Journal homepage
56
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy

Richard N Greenberg Division of Infectious Diseases, University of Kentucky, Lexington, KY, USA
, MD,
Pablo J Cagnoni Bone Marrow Transplant Program, University of Colorado Health Sciences Center, Denver, CO, USA
, MD,
John R Wingard Division of Hematology, University of Florida College of Medicine, Gainesville, FL, USA
, MD,
Mary M Prendergast Fujisawa Healthcare Inc., Deerfield, IL, USA
, MBA &
Kuo B Tong Quorum Consulting, Inc., San Francisco, CA, USACorrespondence[email protected]
, MS
Pages 109-118 | Accepted 09 Jan 2002, Published online: 02 Dec 2008

References

  • Pizzo PA, Robichaud KJ, Gill FA et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. American Journal of Medicine 1982; 72: 101–111.
  • Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New England Journal of Medicine 1999; 340: 764–771.
  • Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clinical and Infectious Diseases 2001; 32: 686–693.
  • Wingard JR, White MH, Anaissie EJ et al. A randomised, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clinical and Infectious Diseases 2000; 31: 1155–1163.
  • Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical and Infectious Diseases 1999; 29: 1402–1407.
  • Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Journal of Clinical Oncology 2000; 18: 2476–2483.
  • Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Wiley; 1972.
  • Greene WH. Econometric Analysis, 3rd edn. Englewood Cliffs, NJ: Prentice Hall; 1998.
  • SPSS 10.0 statistical software, SPSS, Inc. Chicago, IL.
  • Samore MH, Harbarth S, Pestotnik SF et al. Incidence and risk factors for nephrotoxicity (NT) associated with conventional amphotericin B [abstract]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Toronto, Canada. September 2000.
  • Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. Clinical and Infectious Diseases 1999; 29: 1408–1410.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.